|
Wu, Y; Ma, G; Lu, D et al. (1999) Bcr: a negative regulator of the Bcr-Abl oncoprotein. Oncogene 18:4416-24
|
|
Arlinghaus, R B (1998) The involvement of Bcr in leukemias with the Philadelphia chromosome. Crit Rev Oncog 9:1-18
|
|
Wu, Y; Liu, J; Arlinghaus, R B (1998) Requirement of two specific tyrosine residues for the catalytic activity of Bcr serine/threonine kinase. Oncogene 16:141-6
|
|
Oka, T; Sastry, K J; Nehete, P et al. (1998) Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon. Leukemia 12:155-63
|
|
Dawood, M Y; Lau, M; Khan-Dawood, F S (1998) E-cadherin and its messenger ribonucleic acid in periimplantation phase human endometrium in normal and clomiphene-treated cycles. Am J Obstet Gynecol 178:996-1001
|
|
Ma, G; Lu, D; Wu, Y et al. (1997) Bcr phosphorylated on tyrosine 177 binds Grb2. Oncogene 14:2367-72
|
|
Liu, J; Wu, Y; Arlinghaus, R B (1996) Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein. Cancer Res 56:5120-4
|
|
Liu, J; Wu, Y; Ma, G Z et al. (1996) Inhibition of Bcr serine kinase by tyrosine phosphorylation. Mol Cell Biol 16:998-1005
|
|
Wilson-Rawls, J; Xie, S; Liu, J et al. (1996) P210 Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation. Cancer Res 56:3426-30
|
